The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Interleukin‐34 is expressed by giant cell tumours of bone and plays a key role in RANKL‐induced osteoclastogenesis
Abstract
Interleukin‐34 (IL‐34) is a newly discovered regulator of myeloid lineage differentiation, proliferation, and survival, acting via the macrophage‐colony stimulating factor receptor (M‐CSF receptor, c‐fms). M‐CSF, the main ligand for c‐fms, is required for osteoclastogenesis and has been already identified as a critical contributor of the pathogenesis of giant cell tumours of bone (GCTs), tumours rich in osteoclasts. According to the key role of M‐CSF in osteoclastogenesis and GCTs, the expression of IL‐34 in human GCTs was first assessed. Quantitative analysis of IL‐34 mRNA expression in 14 human GCTs revealed expression of this cytokine in GCTs as well as M‐CSF and c‐fms. Immunohistochemistry demonstrated that osteoclast‐like cells exhibited a huge immunostaining for IL‐34 and that mononuclear stromal cells were slightly positive for this protein. In contrast to osteoblasts, bone‐resorbing osteoclasts showed very strong staining for IL‐34, suggesting its potential role in the pathogenesis of GCTs by facilitating osteoclast formation. The role of IL‐34 in osteoclastogenesis was then studied in murine and human models. IL‐34 was able to support RANKL‐induced osteoclastogenesis in the absence of M‐CSF in all models. Multinucleated cells generated in the presence of IL‐34 and RANKL expressed specific osteoclastic markers and resorbed dentine. IL‐34 induced phosphorylation of ERK 1/2 and Akt through the activation of c‐fms, as revealed by the inhibition of signalling by a specific c‐fms tyrosine kinase inhibitor. Furthermore, IL‐34 stimulated RANKL‐induced osteoclastogenesis by promoting the adhesion and proliferation of osteoclast progenitors, and had no effect on osteoclast survival. Overall, these data reveal that IL‐34 can be entirely substituted for M‐CSF in RANKL‐induced osteoclastogenesis, thus identifying a new biological activity for this cytokine and a contribution to the pathogenesis of GCTs. Copyright © 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoclast differentiation and activation
Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003) · Nature · doi:10.1038/nature01658 · Cited by 6,670
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351
Dai, X.-M., Ryan, G. R., Hapel, A. J., Dominguez, M. G., Russell, R. G., Kapp, S., Sylvestre, V., & Stanley, E. R. (2002) · Blood · doi:10.1182/blood.v99.1.111 · Cited by 1,184
Wiktor-Jedrzejczak, W., Bartocci, A., Ferrante, A. W., Ahmed-Ansari, A., Sell, K. W., Pollard, J. W., & Stanley, E. R. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.12.4828 · Cited by 1,031
Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.
Lacey, D. L., Tan, H. L., Lu, J., Kaufman, S., Van, G., Qiu, W., Rattan, A., Scully, S., Fletcher, F., Juan, T., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64556-7 · Cited by 391
Cited by
Cancer to bone: a fatal attraction
Weilbaecher, K. N., Guise, T. A., & McCauley, L. K. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3055 · Cited by 1,285
Lilienthal, I., & Herold, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186885 · Cited by 283
The role of cytokines in inflammatory bone loss
Souza, P. P. C., & Lerner, U. H. (2013) · Immunological Investigations · doi:10.3109/08820139.2013.822766 · Cited by 269
Heymann, M.-F., Lézot, F., & Heymann, D. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.10.011 · Cited by 233
Self-citationSégaliny, A. I., Mohamadi, A., Dizier, B., Lokajczyk, A., Brion, R., Lanel, R., Amiaud, J., Charrier, C., Boisson‐Vidal, C., & Heymann, D. (2015) · International Journal of Cancer · doi:10.1002/ijc.29376 · Cited by 199
Self-citationMizuno, T., Doi, Y., Mizoguchi, H., Jin, S., Noda, M., Sonobe, Y., Takeuchi, H., & Suzumura, A. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.06.011 · Cited by 159
Immunoregulatory properties of the cytokine IL-34
Guillonneau, C., Bézie, S., & Anegon, I. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2482-4 · Cited by 112
Ayturk, U. M., Jacobsen, C. M., Christodoulou, D. C., Gorham, J., Seidman, J. G., Seidman, C. E., Robling, A. G., & Warman, M. L. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1946 · Cited by 84
Metadata
- Authors
- Baud'Huin, M., Renault, R., Charrier, C., Riet, A., Moreau, A., Brion, R., Gouin, F., Duplomb, L., & Heymann, D.
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 2010-04
- Volume
- 221
- Issue
- 1
- Pages
- 77-86
- ISSN
- 0022-3417 (ISSN-L)
- 1096-9896
- OpenAlex
- W2171682032
- Cited by
- 159
- References
- 5
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.